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INTRODUCTION
B-cell precursor acute lymphoblastic leukaemia (BCP-
ALL) is the most common paediatric malignancy and 
the cure rate of this disease has increased enormously 
over the last forty years to a current five-year survival 
of over 90%, attributed to improved chemotherapeutic 
treatment schedules and risk-stratification.1 Neverthe-
less, some patients still experience treatment failure 
after initial therapy and therefore, identification of 
novel biomarkers is critical to distinguish these patients 
at diagnosis, adapt their treatment schedules and to 
develop novel strategies using new therapeutic targets. 
Recent developments in whole genome techniques 
(DNA, RNA, and protein) provided detailed infor- 
mation concerning the molecular alterations important 
for tumour emergence, maintenance and progression. 
Several groups have demonstrated the power of high- 
resolution, genome-wide approaches to identify new 
molecular lesions in leukaemia. As such, deletion, ampli-
fication, point mutation and structural rearrangement 
in genes encoding principal regulators of B lymphocyte 
development and differentiation were identified in 40% 
of B-progenitor ALL cases using single nucleotide poly-
morphism arrays.2-5 
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SUMMARY
Paediatric B-cell precursor acute lymphoblastic leukaemia arises from recurrent genetic lesions that block 
precursor B-cell differentiation and drive aberrant proliferation and cell survival. Risk-adapted intensive 
chemotherapy has been a major breakthrough in reaching the current survival rates of >90% for this ALL 
subtype. Recent developments in genome-wide genetic analysis have provided a wide range of chromosomal 
and genomic abnormalities characterising B-cell precursor acute lymphoblastic leukaemia, several of which 
are associated with patient outcome. This article summarises the results of several studies performed during 
the PhD thesis of Dr Farzaneh Ghazavi. This research project has led to the identification of a novel molecular 
lesion predicting poor outcome, a novel targetable pathway in a subgroup of B-cell precursor acute lympho-
blastic leukaemia patients and resulted in the identification of an ETV6/RUNX1-specific long non-coding 
RNA signature providing novel biological insights into ETV6/RUNX1-mediated leukemogenesis.
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This paper discusses the results obtained through 
studying the genome, long non-coding repertoire and 
proteome during the PhD thesis of Dr Farzaneh Ghazavi 
and provides future perspectives.
IDENTIFICATION OF CD200/BTLA 
DELETIONS IN PAEDIATRIC BCP-ALL 
TREATED ACCORDING TO THE  
EORTC-CLG 58951 PROTOCOL
The advent of high-resolution, microarray-based tech-
niques such as array-based comparative genomic hybridi-
sation (CGH) has enabled the identification of multiple 
novel DNA copy number alterations targeting key cel-
lular pathways in ALL. Some of the identified genetic 
lesions are clinically relevant and can be integrated into 
the risk classification of the ALL patients, as recently 
reviewed by Ghazavi et al.2-5 Nevertheless; novel prog-
nostic markers need to be discovered, as illustrated by 
the observation that a considerable number of relapses 
remain molecularly unexplained. 
To identify new genetic lesions with prognostic relevance 
in BCP-ALL, we performed copy number profiling on 
leukemic blasts of BCP-ALL patients treated with the 
EORTC-CLG 58951 protocol. This analysis revealed 
a recurrent deletion of a genomic region (~164kb) at 
chr3q13.2, encompassing the lymphoid signalling mole-
cules BTLA (CD272) and CD200 genes, in 10% (7 out 
of 70) of the initial group and 4.8% (56 out of 1,154) of 
an extended cohort of BCP-ALL patients.6 Mapping the 
exact breakpoint of CD200/BTLA deletions in primary 
leukaemia genomes demonstrated that the deletions 
mostly affected the whole genomic sequence of both 
CD200 and BTLA genes and that the deletions were 
likely mediated by abnormal RAG activity, as evidenced 
by the RAG recognition sequence motif adjacent to the 
genomic breakpoints. In line with recent reports that 
identified aberrant RAG recombinase activity as one 
of the main mechanisms that drive the generation of 
cooperative genomic lesions in ETV6/RUNX1-positive 
BCP-ALL, we found that CD200/BTLA deletions were 
strongly associated with t(12;21) positive leukaemia 
(p<0.0001), suggesting a genetic interaction between 
loss of CD200/BTLA and expression of ETV6/RUNX1 
during leukemic transformation.7 The presence of CD200/
BTLA deletions did not affect the favourable prognosis 
of ETV6/RUNX1-positive BCP-ALLs. However, and most 
notably, CD200/BTLA deletions were associated with 
inferior event-free survival, both in the complete patient 
population (HR 2.02; 95% CI 1.23-3.32; p=0.005) 
as well as in the intermediate genetic risk group (HR 4; 
99% CI 1.34-11.93; p<0.001). In addition, multivariate 
analysis confirmed the independent prognostic value 
of CD200/BTLA deletion in the whole cohort of BCP-
ALLs. Altogether, these data suggest the added value of 
CD200/BTLA status in the risk stratification algorithm 
of BCP-ALL patients.
RPPA-BASED PROTEIN PROFILING IN 
ETV6/RUNX1-POSITIVE ACUTE 
LYMPHOBLASTIC LEUKAEMIA PATIENTS 
WITH LOW CD200 EXPRESSION
Identification of altered signalling pathways is of utmost 
importance in cancer therapy since many of these 
pathways are targetable and thus a potential bull’s eye 
for increasing treatment efficiency.8-10 We focused on the 
further elucidation of the signalling pathways affected 
by the recurrent deletion of CD200 and BTLA, which 
was previously identified.6 Importantly, both CD200 
and BTLA genes, affected by the deletion, encode 
lymphoid signalling molecules and have been shown 
to inhibit activation of B-cell receptor (BCR) and 
MAPK/PI3K signalling, respectively, which are both 
essential signalling pathways for B-cell proliferation and 
maturation.11,12 In addition, activation of BTLA upon 
interaction with its ligand HVEM, attenuates B-cell 
proliferation as a result of reduced activation of signalling 
molecules downstream of BCR. Moreover, crosstalk 
between CD200 and its receptor CD200R has been 
shown to mediate the inhibition of Ras/MAPK sig- 
nalling pathway through recruitment of SHIP and/or 
RasGAP and subsequently deactivation of signalling 
molecules such as ERK, JNK, and p38 MAPK.12
To further explore the functional consequences of 
reduced CD200 expression on the activity of downstream 
signalling pathways, reverse phase protein microarray 
(RPPA) analyses was applied (Ghazavi et al., in prepara-
tion). Using this technique we determined the expres-
sion and phosphorylation level of 87 signalling molecules 
in 72 BCP-ALL patients’ specimens. Interestingly, diffe-
rential expression analysis of proteins/phosphoproteins 
between patients with low and high expression of 
CD200 revealed significant upregulation and hyper- 
phosphorylation of proteins involved in PI3K/AKT/
mTOR signalling pathway in patients with low CD200 
expression. Notably, this pathway is an essential regu-
lator of many cellular processes such as protein syn- 
thesis, proliferation and apoptosis and its constitutive 
activation in many forms of malignancies attests its 
pathogenetic importance.13,14 Finally, we evaluated the 
potential of PI-103, a novel dual inhibitor of PI3Kalpha 
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and mTOR to inhibit growth in CD200 low cells.15,16 
A 72h treatment of REH cells, a cell line carrying a 
deletion of CD200, showed that PI-103 treatment sig-
nificantly reduces the phosphorylation levels of AKT, 
c-RAF and eIF4G and affects survival.
UNIQUE LONG NON-CODING RNA 
EXPRESSION SIGNATURE IN ETV6/
RUNX1-DRIVEN B-CELL PRECURSOR 
ACUTE LYMPHOBLASTIC LEUKAEMIA
Mammalian genomes comprise ~ 20000 protein- 
coding genes, only representing <2% of the total genome 
sequence, whereas more than 90% of the genome is 
actively transcribed into non-coding RNA (ncRNA). The 
latter group of RNAs consists of small structural and 
regulatory RNAs (including rRNAs, tRNAs, snoRNAs 
and microRNAs) and long non-coding RNAs (lncRNAs, 
>200 nucleotides).17,18 More than 10,000 lncRNAs have 
been annotated so far in the human genome sequence.19,20 
Functional studies, although limited, revealed that 
lncRNAs regulate many cellular processes including 
chromatin modification, transcriptional and post-trans- 
criptional regulation, mRNA degradation and trans- 
lation, and trafficking of molecules across the nuclear 
membrane.21-26 Different studies have recently shown 
that aberrant expression of non-coding RNAs such as 
long non-coding RNAs (lncRNA) might contribute to 
the development and progression of leukaemia.27,28 
Identification of disease-associated lncRNAs would not 
only provide new insights into our understanding of 
disease mechanisms but might also reveal new prog-
nostic biomarkers or novel therapeutic targets for the 
treatment of diseases. 
Recently, we established an ETV6/RUNX1-specific 
lncRNA signature by performing expression profiling 
microarray in a set of 64 primary BCP-ALL patients 
including 25 ETV6/RUNX1-positive, seven TCF3/PBX1- 
positive, fifteen hyperdiploid and seventeen normal 
karyotype BCP-ALLs.29 The integration of these lncRNA 
expression data with RNA sequencing results from a 
panel of thirteen human BCP-ALL leukaemia cell lines, 
resulted in the identification of sixteen lncRNAs exclu-
sively associated with the presence of the ETV6/
RUNX1 fusion protein. 
Complemented with shRNA-mediated silencing of 
endogenous ETV6/RUNX1 in an ETV6/RUNX1-positive 
BCP-ALL cell line, the list of ETV6/RUNX1 associated 
lncRNAs was narrowed down from sixteen to four 
lncRNAs including lnc-NKX2-3-1, lnc-TIMM21-5, lnc- 
ASTN1-1, and lnc-RTN4R-1. 
Finally, in vitro knockdown using LNA™ GapmeR tech-
nology suggested that lnc-TIMM21-5 and lnc-ASTN1-1 
are probably not involved in transcriptional regulation 
but, in contrast, lnc-NKX2-3-1 and lnc-RTN4R-1 perturba-
tions resulted in a severe effect on overall transcription. 
CONCLUSION
Altogether, the data obtained during this PhD thesis 
have contributed to the identification of a novel prog-
nostic factor - CD200/BTLA deletion - in BCP-ALL, the 
elucidation of the signalling pathways downstream of 
these molecules and delivered fundamental proof that 
lncRNAs play an important role in distinct subtypes of 
BCP-ALL.
It will be essential to validate the prognostic power of 
CD200/BTLA deletions in an independent cohort. Since 
our results are clinically relevant, the biotech company 
MRC Holland (www.mrcholland.com) has decided to 
include this alteration in their MLPA assays used by 
many centres for diagnostic work-up of paediatric ALL. 
The identification of hyperactive PI3K/AKT/mTOR 
signalling pathway in BCP-ALLs with low CD200 
expression provides a rationale for future experiments 
using inhibitors of PI3K/mTOR and translation path-
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KEY MESSAGES FOR CLINICAL PRACTICE
1 CD200/BTLA deletions are associated with poor prognosis in BCP-ALL.
2 PI3K/AKT/mTOR signalling pathway might serve as a targetable pathway for treatment of BCP-ALL  
patients with low CD200 expression.
3 lncRNA expression profiling might reveal new prognostic biomarkers and novel therapeutic targets for 
the treatment of BCP-ALL patients.
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ways in this subgroup of patients. Although our in vitro 
experiments look very promising, it will be essential to 
further confirm these findings in vivo using xenograft 
models of primary patient material.
Finally, the data generated in the last part of the study 
identified a panel of ETV6/RUNX1-specific lncRNAs 
that might be implicated in the biology of human 
BCP-ALL and could serve as novel therapeutic targets 
for the treatment of this prevalent subtype of human 
leukaemia. Further functional studies of the identified 
lncRNAs, including the identification of binding partners, 
should be performed in order to bring these findings to 
information impacting on the clinical management of 
patients.
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